MoonLake Immunotherapeutics Class A MLTX 深 沪
等待开盘 01-15 09:30:00 美东时间
17.41
+0.310
+1.81%
华盛通- 最 高17.91
- 今 开17.12
- 成交量 196.69万股
- 最 低 17.02
- 昨 收 17.10
- 总市值 12.43亿
- 52周最高 62.75
- 市盈率 静 --
- 换手率 2.76%
- 52周最低 5.95
- 委 比 84.84%
- 总股本 7137.36万
- 历史最高 64.98
- 量 比 0.21
- 振 幅 5.20%
- 历史最低 4.25
- 每 手 1
- 风险率 16.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
BTIG Upgrades MoonLake to Buy, Announces $24 Price Target
BTIG analyst Julian Harrison upgrades MoonLake (NASDAQ:MLTX) from Neutral to Buy and announces $24 price target.
01-09 18:58
美股牛股 | 获FDA支持加速药物上市！MoonLake大涨27%；Satellogic大涨21.7%
获FDA支持加速药物上市！MoonLake大涨27%；宣布获七位数地球观测合同，Satellogic涨超21%>>
01-09 16:01
MoonLake Immunotherapeutics shares are trading higher after the company said FDA feedback confirmed it may establish substantial evidence of effectiveness for hidradenitis suppurativa without additional clinical trials.
MoonLake Immunotherapeutics shares are trading higher after the company said FD...
01-08 21:27
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
MoonLake Immunotherapeutics requested a Type B meeting with the FDA to discuss the clinical evidence strategy for its Sonelokimab (SLK) in Hidradenitis Suppurativa (HS). The FDA confirmed that MoonLake can establish substantial evidence of effectiveness (SEE) without additional clinical trials, using data from its existing VELA-1, VELA-2, and MIRA trials. MoonLake plans to submit a BLA for SLK in HS in H2 2026. An Investor Day will be held on Feb...
01-08 13:00
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
HC Wainwright & Co. Maintains Buy on MoonLake, Lowers Price Target to $26
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy and lowers the price target from $30 to $26.
2025-11-21 19:23
MoonLake Reports Clinical Data From Sonelokimab Studies, Nanobody Drug Shows Results In Multiple Trials For Rare Skin Diseases, Eyes FDA Filing In 2026
MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results
2025-11-05 20:21
MoonLake Q3 EPS $(1.10) Misses $(0.88) Estimate
MoonLake (NASDAQ:MLTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(0.88) by 25.14 percent. This is a 96.43 percent decrease over losses of $(0.56) per share from the
2025-11-05 20:13
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
